Article ID Journal Published Year Pages File Type
34478 Process Biochemistry 2015 7 Pages PDF
Abstract

•Co-expression of carbonyl reductase and glucose dehydrogenase was achieved in a favorable order.•Exogenous addition of cofactors was completely eliminated for the bioreduction.•Whole-cell based biocatalytic process was established for the preparation of statin side chains.

Statins are the most effective drugs for hyperlipidemia-related diseases by competitively inhibiting 3-hydroxy-3-methylglutaryl coenzyme A reductase. Because of the difficulty and environmental concerns associated with chemical preparation of the chiral diols of statin side chains, different biocatalytic approaches have been explored and the two-step bio-reduction process for the introduction of two chiral hydroxyl groups has been industrialized. However, the high costs and poor stability of nicotinamide cofactors in the process was a major limiting factor. In the present study, a whole-cell biocatalyst simultaneously expressing carbonyl reductase and glucose dehydrogenase was constructed. This biocatalyst was then used to synthesize t-butyl-6-cyano-(3R, 5R)-dihydroxyhexanoate via enzymatic reduction of t-butyl-6-cyano-(5R)-hydroxy-3-carboxylhexanoate, which involves in the self-recycling of endogenous cofactors. After systematic optimization, the bioconversion was complete with a productivity of 120 g l−1 day−1 without exogenous addition of cofactors after 7 h at 35 g/L substrate concentration. Thus, the present system has simplified the process and improved the overall efficiency for the preparation of statin side chains.

Related Topics
Physical Sciences and Engineering Chemical Engineering Bioengineering
Authors
, , ,